1. European Medicines Agency, Evaluation of Medicines for Human Use, Ixempra Withdrawal Assessment Report—EUROPA—EU website PDF (2009). http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500062429.pdf .
2. Denduluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Canc. 2011;11(3):139–45.
3. Fornier MN. Ixabepilone first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Canc. 2007;7(10):757–63.
4. Xu XS, Zeng J, Mylott W, Arnold M, Waltrip J, Iacono L, Mariannino T, Stouffer B. Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, IxempraTM) in human plasma: method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants. J Chromatogr B. 2010;878(5–6):525–37.
5. Magadala P, LE Vlerken, Shahiwala A, Amiji MM. Multifunctional polymeric nanosystems for tumor-targeted delivery. In: Torchilin VP, editor. Multifunctional pharmaceutical nanocarriers, vol. 4. New York: Springer; 2008. p. 33–64.